Niox shareholders approve share buyback of up to £12.5 million with 99.17% support
Key Facts
Niox Group shareholders approved the share buyback offer resolution with 99.17% of votes cast, according to voting results reported by Investing.com. The offer aims to return up to £12.5 million to shareholders if fully subscribed, according to the company's interim results disclosure. The group's official financial calendar scheduled the general meeting for the offer for 21 October 2026 as part of the buyback approval process. The resolution received 297,460,912 votes in favour and 2,502,197 against, representing 0.83% of total votes cast. Niox itself will purchase shares from its shareholders, returning cash to them under the group's capital allocation policy. Shareholder approval of the resolution comes ahead of the announcement of the offer results, which the company said would be released on Thursday, according to the platform.
Under the offer terms set out in its interim results announcement, Niox seeks to repurchase up to 15,625,000 shares at 80 pence a share. The offer price represents a 22.0% premium to the reference closing mid-market price, according to proposal details published by Investing.com. That reference price was 65.6 pence a share on 28 September 2026, the date used for the comparison in the offer terms. The group said in its disclosure that the transaction aims to "repurchase 15,625,000 shares at 80 pence a share, returning £12.5 million". Returning the maximum amount of cash to shareholders remains conditional on full subscription to the buyback offer, according to the terms announced by the company.
The transaction forms part of a capital allocation policy targeting the return of at least 80% of free cash flow to shareholders over the medium term. According to the group's investor presentation, total cash returned to shareholders over the past four years will reach about £60 million, including the offer if fully subscribed. The group's cash balance stood at £17.4 million on 31 August 2026, according to the interim results disclosure, which provided liquidity context ahead of the transaction. Niox described its balance sheet in the investor presentation as "debt-free", alongside its targets for returning cash flow to shareholders. The group's policy combines returning surplus cash to shareholders with continued investment in growth, the framework under which it presented the offer to buy back a portion of its shares.
On financial performance, Niox's first-half revenue was £24.0 million, compared with £25.2 million in the comparative period, according to the results announcement. Adjusted earnings before interest, taxes, depreciation and amortisation were £8.3 million in the first half, compared with £9.2 million in the prior period. Gross margin, meanwhile, rose to 71% from 70% in the comparative period, according to figures announced by the group. The improvement in gross margin coincided with declines in both revenue and adjusted earnings between the two half-year periods. The offer to return cash to shareholders thus comes against a backdrop of interim results that combined lower revenue with an improved gross margin.
Business details in the interim results investor presentation showed diverging clinical and research revenues during the period reported by the group. Clinical revenue rose to £20.6 million from £20.0 million in the previous first half, an increase of 3%. Research revenue fell to £3.4 million in the first half from £5.2 million in the comparative period. The annual decline in research revenue was 33%, according to the company's presentation, compared with growth in clinical revenue over the same period. The decline in the group's overall revenue accompanied this divergence between the two businesses, as increased clinical revenue coincided with falling research revenue.
Niox provides its products and services through direct sales and a distributor network in more than 50 countries, according to the group's interim results disclosure. On product development, the company announced that its Niox Pro device had received CE marking and approval from Britain's Medicines and Healthcare products Regulatory Agency. The group expects an improvement in the second half, supported by the device's launch, price increases in Japan and increased clinical trial activity. It identified the supporting factors in its investor presentation as "the launch of Niox Pro, pricing in Japan, and increased clinical trial activity". The company places the device's launch among the drivers of the expected improvement, alongside the pricing and trial activity factors cited in its outlook. On the buyback, the next step following the shareholder meeting scheduled for 21 October 2026 remains the announcement of the offer results on Thursday, according to Investing.com's account of the company's statement.